- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
You are here
Trial Search
Trial Name | Prevention Option | Phase | Start Date | Sponsors | Countries | Population | Candidate(s) | Status |
---|---|---|---|---|---|---|---|---|
IAVI G002 | HIV Vaccine | I | November 2021 | International AIDS Vaccine Initiative; ModernaTX, Inc.; The University of Texas at San Antonio; George Washington University; Fred Hutchinson Cancer Research Center; Emory University | Men, Women | Ongoing | ||
HVTN 706/ HPX3002 Mosaico | HIV Vaccine | III | October 2019 | Janssen Vaccines & Prevention B.V. | United States of America, Argentina, Italy, Mexico, Peru, Poland, Spain | Men | Ad26.Mos4.HIV, gp140 | Ongoing |
PV1/PrEPVacc | HIV Vaccine, PrEP | IIb | January 2020 | Sponsor: Imperial College London. Coordinating partners: P Kaleebu, E Ruzagira (MRC/UVRI & LSHTM, Uganda); J Weber/J Fox/C Kingsley (Imperial College, UK); S McCormack (UCL, UK); K Chinyenze (IAVI-Kenya); G Pantaleo/S Ding (CHUV/EVF, Switzerland) | Uganda, South Africa, United Republic of Tanzania, Mozambique | Men, Women | DNA , MVA, Protein | Ongoing |
HVTN 115/ EnvSeq-1 and CH505 | HIV Vaccine | I | August 2017 | NIAID (DAIDS-ES: 12042) | United States of America | Men, Women | CH505TF | Ongoing |
HVTN 118/ HPX 2003/ IPCAVD 012/ ASCENT | HIV Vaccine | I/II | March 2017 | Janssen, HVTNNIAID, MHRP, BIDMC, Ragon | United States of America, Kenya, Rwanda | Men, Women | Ad26.Mos.HIV, gp140 | Ongoing |
HVTN 117/ HPX2004/ IPCAVD011/ TRAVERSE | HIV Vaccine | I/II | July 2016 | National Institutes of Health, Henry M Jackson Foundation for Advancement of Military Medicine and the US Department of Defense, Ragon Institute of MGH, MIT, & Harvard, Bill & Melinda Gates Foundation, and Janssen Vaccines & Prevention | United States of America, Rwanda | Men, Women | Ad26.Mos.HIV, gp140 | Ongoing |
RV328/ AIDSVAX | HIV Vaccine | II | July 2014 | U.S. Army Medical Research and Materiel Command, NIH | Thailand | Men, Women | AIDSVAX | Ongoing |
HVTN 110 | HIV Vaccine | I | March 2015 | Emergent BioSolutions, NIAID | United States of America | Men, Women | Ad4, AIDSVAX, gp120 | Ongoing |
HVTN 107/ ALVAC-HIV (vCP2438) | HIV Vaccine | I/II | July 2017 | NIAID | South Africa, Mozambique, Zimbabwe | Men, Women | ALVAC, gp120 | Ongoing |
HVTN 702 | HIV Vaccine | III, IIb | October 2016 | NIAID, Bill and Melinda Gates Foundation, GlaxoSmithKline, Sanofi | South Africa | Men, Women | ALVAC, gp120 | Ongoing |
HIV-V-A004/ IPCAVD 009 (APPROACH) | HIV Vaccine | I/II | December 2014 | Crucell Holland BV; Collaborators include: US National Institute of Allergy and Infectious Diseases Division of AIDS (US NIAID); US Military HIV Research Program (US MHRP); Beth Israel Deaconess Medical Center; International AIDS Vaccine Initiative (IAVI) | United States of America, Rwanda, South Africa, Thailand, Uganda | Men, Women | Ad26.Mos.HIV, gp140, MVA | Ongoing |
RV 306 | HIV Vaccine | II | September 2013 | US Army Medical Research and Materiel Command; National Institute of Allergy and Infectious Diseases (NIAID) | Thailand | Men, Women | AIDSVAX, ALVAC | Ongoing |
RV 305 | HIV Vaccine | II | April 2012 | US Army Medical Research and Materiel Command; National Institutes of Health (NIH) | Thailand | Men, Women | AIDSVAX, ALVAC | Ongoing |